If the maximum fair prices (MFPs) the U.S. CMS announced after the first round of drug price negotiations are any indication, advocates of the government price setting may be settling for short-term ...

Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s ...

Currently, cancer therapy trial-and-error methodology is inefficient and unsustainable. Oncology is the worst therapeutic ...

Regenerative medicine company Orthocell Ltd. raised AU$17 million (US$11.28 million) to launch its nerve repair product, Remplir, in the $1.6 billion U.S. market.

Delta-like ligand 3 (DLL3) is a highly relevant target for radiopharmaceutical therapy due to its expression in more than 85% of tumors of patients with small-cell lung cancer.

Cancer Research UK and Kisoji Biotechnology Inc. have signed an agreement to bring Kisoji's naked anti-TROP2 antibody, KJ-103, into a first-in-human trial. KJ-103 is a single domain antibody that ...

Visterra Inc., a subsidiary of Otsuka Pharmaceutical Co. Ltd., reported positive top-line data from the ongoing Visionary phase III study of sibeprenlimab, an anti-APRIL monoclonal antibody for ...

Aevisbio Inc. and the Korea Research Institute of Chemical Technology have jointly developed new compounds targeting protein cereblon (CRBN) reported to be useful for the treatment of cancer.

Bayer AG has entered into an exclusive licensing agreement with Dewpoint Therapeutics Inc. for a heart disease program to treat dilated cardiomyopathy (DCM) patients characterized by specific ...

Despite an outcome that TD Cowen analyst Tyler Van Buren called ”fantastic,” shares of Tyra Biosciences Inc. (NASDAQ:TYRA) closed Oct. 25 at $21.93, down $6.68, or 23%, as Wall Street digested new ...

Beijing Primegene Therapeutics Co. Ltd. has patented macrocyclic compounds acting as non-receptor tyrosine-protein kinase TYK2 (JH2 domain) allosteric inhibitors reported to be useful for the ...

Children with autism spectrum disorder (ASD) often must wait years before they get a diagnosis, and that wait time can result in missed opportunities for changing behaviors associated with autism.